GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Equity-to-Asset
中文

Daiichinkyo Co (Daiichinkyo Co) Equity-to-Asset : 0.49 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Daiichinkyo Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $11,018 Mil. Daiichinkyo Co's Total Assets for the quarter that ended in Dec. 2023 was $22,704 Mil. Therefore, Daiichinkyo Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.49.

The historical rank and industry rank for Daiichinkyo Co's Equity-to-Asset or its related term are showing as below:

DSNKY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49   Med: 0.62   Max: 0.67
Current: 0.49

During the past 13 years, the highest Equity to Asset Ratio of Daiichinkyo Co was 0.67. The lowest was 0.49. And the median was 0.62.

DSNKY's Equity-to-Asset is ranked worse than
61.55% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs DSNKY: 0.49

Daiichinkyo Co Equity-to-Asset Historical Data

The historical data trend for Daiichinkyo Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Equity-to-Asset Chart

Daiichinkyo Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.62 0.61 0.61 0.58

Daiichinkyo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.58 0.59 0.60 0.49

Competitive Comparison of Daiichinkyo Co's Equity-to-Asset

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Equity-to-Asset falls into.



Daiichinkyo Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Daiichinkyo Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=10817.054/18770.075
=0.58

Daiichinkyo Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=11017.652/22703.924
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (OTCPK:DSNKY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Daiichinkyo Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.